Previous 10 | Next 10 |
Gainers: Sportradar Group AG (SRAD) +5%. Eargo, Inc. (EAR) +4%. Zynex, Inc. (ZYXI) +3%. IVERIC bio, Inc. (ISEE) +3%. Sono Group N.V. (SEV) +3%. Losers: Vir Biotechnology, Inc. (VIR) -8%. Jounce Therapeutics, Inc. (JNCE) -6%. Travelzoo (TZOO) -5%. Health Catalyst, Inc (HCAT) -4%...
Jefferies Financial Group started off coverage on Iveric Bio (NASDAQ:ISEE) in a report issued on Tuesday. The firm sets a "Buy" rating on the stock with a price target of $27. Jeffries' price objective suggests a potential upside of 71.54% from the stock's last close. The move sends Iveric sh...
Biotech has been the worst performing sector of the stock market across the past 12 months. That seems improbable given e.g. the discovery of MRNA vaccines, breakthroughs in gene therapy etc. But the hype cycle hit its peak in 2021 with too many big-money IPOs. The sector is down ...
IVERIC bio, Inc. (Nasdaq: ISEE) announced today that Glenn P. Sblendorio, Chief Executive Officer, will participate in a fireside chat at the Cowen 42 nd Annual Health Care Conference on Monday, March 7, 2022, at 11:10 a.m. Eastern Time. Investors and the general public are ...
Image source: The Motley Fool. IVERIC bio, Inc. (NASDAQ: ISEE) Q4 2021 Earnings Call Feb 24, 2022 , 8:00 a.m. ET Kathy Galante Continue reading For further details see: IVERIC bio, Inc. (ISEE) Q4 2021 Earnings Call Transcript
IVERIC bio, Inc. (ISEE) Q4 2021 Earnings Conference Call February 24, 2022 08:00 AM ET Company Participants Kathy Galante - Senior Vice President of Investor Relations Glenn Sblendorio - Chief Executive Officer Keith Westby - Chief Operating Officer Pravin Dugel - President Tony Gibney - Exec...
IVERIC bio press release (NASDAQ:ISEE): Q4 GAAP EPS of -$0.29 misses by $0.04. The Company estimates its year-end 2022 cash, cash equivalents and marketable securities will range between $215 million and $225 million. The Company also estimates that its cash, cash equivalents and available fo...
- Zimura ® GATHER2 Topline Data Expected in the Second Half of 2022 - - GATHER2 Trial Completion at 84% for Year One; Patient Retention Continues to Exceed Expectations with a 12-Month Injection Fidelity Rate Target Greater than 90% – - Internal Efforts...
IVERIC bio (NASDAQ:ISEE) is scheduled to announce Q4 earnings results on Wednesday, February 23rd, after market close. The consensus EPS Estimate is -$0.24 (+11.1% Y/Y). Over the last 3 months, EPS estimates have seen 0 upward revisions and 1 downward. For further details see: IVERIC bi...
ABEV,ACIW,ACRS,AEP,AGIO,AHCO,ALIM,AMT,ATHM,OTCQX:AXAHY,AZUL,BABA,BLI,BUD,CARS,CBRE,CCO,CCOI,OTCPK:CDUAF,CGEN,CLDT,CMPS,CWT,CYD,DAO,DBRG,OTCPK:DDAIF,DEN,DISCA,DISH,DOCN,OTCQX:DTEGY,EDIT,ELAN,EME,EXPI,FOLD,GCI,GLNG,GNK,GNL,GTLS,HMHC,HYLN,IBP,IMUX,IONS,IRM,ISEE,KDP,KRP,OTCPK:LBLCF,LNG,LNTH,LXP,L...
News, Short Squeeze, Breakout and More Instantly...
Astellas Completes Acquisition of Iveric Bio PR Newswire TOKYO and PARSIPPANY, N.J. , July 11, 2023 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura , "Astellas") today announced that it has successfully completed the acquisit...
Shares of IVERIC bio, Inc. (NASDAQ: ISEE) traded at a new 52-week high today and are currently trading at $39.73. So far today, approximately 1.78M shares have been exchanged, as compared to an average 30-day volume of 5.04M shares. IVERIC bio, Inc., a biopharmaceutical company, discovers and...
IVERIC bio, Inc. (NASDAQ: ISEE) has caught the attention of the investment community today with its bullish price action. The company's shares are currently up 1.93% on the day to $38.77. IVERIC bio, Inc., a biopharmaceutical company, discovers and develops novel treatments for retinal disease...